CFDE Data Portal | Search CDK9

	Label	Description
	GSE202744 CDK9 inhibition Toyocamycin 1 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE169090 CDK9 inhibition 3 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE189695 CDK9 ALK inhibition 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE202744 CDK9 inhibition Toyocamycin 1 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	CDK9 associations Collection (Entity type)	Associations for CDK9_associations
	GSE102757 1 V 0 PANOBINOSTAT MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE207871 NPC knockdown S18 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	CDK9 Down Gene Set (Entity type)	A Gene Set from LINCS
	CDK9 Up Gene Set (Entity type)	A Gene Set from LINCS
	GSE97616 GSE97617 NOK overexpression HEK RNA Small Interfering 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS

GSE202744 CDK9 inhibition Toyocamycin 1 v 3 human dn

A Gene Set from LINCS

GSE169090 CDK9 inhibition 3 v 0 human dn

A Gene Set from LINCS

GSE189695 CDK9 ALK inhibition 1 v 0 human up

A Gene Set from LINCS

GSE202744 CDK9 inhibition Toyocamycin 1 v 3 human up

A Gene Set from LINCS

CDK9 associations

Associations for CDK9_associations

GSE102757 1 V 0 PANOBINOSTAT MOUSE UP

A Gene Set from LINCS

GSE207871 NPC knockdown S18 1 v 0 human up

A Gene Set from LINCS

CDK9 Down

A Gene Set from LINCS

CDK9 Up

A Gene Set from LINCS

GSE97616 GSE97617 NOK overexpression HEK RNA Small Interfering 0 v 1 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.